Edition:
United Kingdom

Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,557JPY
13 Sep 2019
Change (% chg)

¥20 (+1.30%)
Prev Close
¥1,537
Open
¥1,545
Day's High
¥1,564
Day's Low
¥1,534
Volume
9,904,700
Avg. Vol
5,699,747
52-wk High
¥2,056
52-wk Low
¥1,356

Select another date:

Mon, Jun 3 2019

Photo

Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

UPDATE 1-Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study

June 3 An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

CORRECTED-Seattle Genetics, Astellas drug shows rapid tumor shrinkage in advanced bladder cancer study

June 3 An experimental drug developed by Seattle Genetics Inc and Astellas Pharma Inc led to significant, rapid tumor shrinkage in patients with advanced bladder cancer who had been previously treated with immunotherapy and chemotherapy in a midstage trial, according to data presented on Monday.

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

BOSTON Two drugmakers will pay nearly $125 million (97 million pounds) to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe

BOSTON Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

UPDATE 3-Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

BOSTON, April 25 Two drugmakers will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications, the U.S. Justice Department said on Thursday.

Drugmakers Astellas, Amgen to pay $125 mln in U.S. charity kickback probe

BOSTON, April 25 Two drugmakers will pay nearly $125 million to settle claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their medications, the U.S. Justice Department said on Thursday.

Select another date: